NASDAQ:AMRN - Nasdaq - US0231112063 - ADR - Currency: USD
0.594
+0 (+0.49%)
The current stock price of AMRN is 0.594 USD. In the past month the price increased by 8.63%. In the past year, price decreased by -50.08%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.85 | 354.98B | ||
AMGN | AMGEN INC | 15.03 | 159.99B | ||
GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
NTRA | NATERA INC | N/A | 22.20B | ||
BIIB | BIOGEN INC | 8.32 | 19.98B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
AMARIN CORP PLC -ADR
First Floor, Block 3, The Oval,, Shelbourne Road, Ballsbridge
DUBLIN Dublin 2 IE
CEO: John F. Thero
Employees: 275
Company Website: https://amarincorp.com/
Investor Relations: https://amarincorp.com/investor-relations
Phone: 35316699020
The current stock price of AMRN is 0.594 USD. The price increased by 0.49% in the last trading session.
The exchange symbol of AMARIN CORP PLC -ADR is AMRN and it is listed on the Nasdaq exchange.
AMRN stock is listed on the Nasdaq exchange.
8 analysts have analysed AMRN and the average price target is 1.02 USD. This implies a price increase of 71.72% is expected in the next year compared to the current price of 0.594. Check the AMARIN CORP PLC -ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AMARIN CORP PLC -ADR (AMRN) has a market capitalization of 244.33M USD. This makes AMRN a Micro Cap stock.
AMARIN CORP PLC -ADR (AMRN) currently has 275 employees.
AMARIN CORP PLC -ADR (AMRN) has a support level at 0.54 and a resistance level at 0.6. Check the full technical report for a detailed analysis of AMRN support and resistance levels.
The Revenue of AMARIN CORP PLC -ADR (AMRN) is expected to decline by -31.86% in the next year. Check the estimates tab for more information on the AMRN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AMRN does not pay a dividend.
AMARIN CORP PLC -ADR (AMRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).
The outstanding short interest for AMARIN CORP PLC -ADR (AMRN) is 4.16% of its float. Check the ownership tab for more information on the AMRN short interest.
ChartMill assigns a technical rating of 5 / 10 to AMRN. When comparing the yearly performance of all stocks, AMRN is a bad performer in the overall market: 86.47% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to AMRN. While AMRN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months AMRN reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 30.77% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -5.24% | ||
ROE | -7.4% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to AMRN. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -2% and a revenue growth -31.86% for AMRN